The week in pharma: action, reaction and insight – week to April 18

21 April 2025

By Barbara Obstoj-Cardwell. Editor

On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in myasthenia gravis. By contrast, US pharma giant Pfizer announced disappointing results for its obesity candidate danuglipron and its decision to discontinue development. Meantime, Eli Lilly’s shares leapt after it reported strong Phase III trial data on its diabetes and obesity candidate orforglipron. Additionally, there was welcome news last week for pharma companies operating in the USA, when US President Donald Trump issued an executive order calling for the scrapping of the Inflation Reduction ACT (IA) so-called pill penalty.

Remegen eyes competitive DMT market with telitacicept

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK